Logo image of MRT

MARTI TECHNOLOGIES INC (MRT) Stock Fundamental Analysis

USA - NYSEARCA:MRT - US5731341039 - Common Stock

2.41 USD
+0.07 (+2.99%)
Last: 10/3/2025, 8:04:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MRT. MRT was compared to 42 industry peers in the Ground Transportation industry. Both the profitability and financial health of MRT have multiple concerns. MRT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MRT had negative earnings in the past year.
MRT had a negative operating cash flow in the past year.
MRT had negative earnings in each of the past 5 years.
MRT had a negative operating cash flow in each of the past 5 years.
MRT Yearly Net Income VS EBIT VS OCF VS FCFMRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

MRT's Return On Assets of -183.73% is on the low side compared to the rest of the industry. MRT is outperformed by 90.48% of its industry peers.
Industry RankSector Rank
ROA -183.73%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRT Yearly ROA, ROE, ROICMRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -0.5 -1 -1.5

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRT Yearly Profit, Operating, Gross MarginsMRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

MRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRT Yearly Shares OutstandingMRT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 10M 20M 30M 40M
MRT Yearly Total Debt VS Total AssetsMRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M

2.2 Solvency

MRT has an Altman-Z score of -5.40. This is a bad value and indicates that MRT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.40, MRT is doing worse than 85.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.4
ROIC/WACCN/A
WACC9.36%
MRT Yearly LT Debt VS Equity VS FCFMRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

MRT has a Current Ratio of 1.47. This is a normal value and indicates that MRT is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.47, MRT is doing good in the industry, outperforming 71.43% of the companies in the same industry.
A Quick Ratio of 1.32 indicates that MRT should not have too much problems paying its short term obligations.
MRT has a Quick ratio of 1.32. This is in the better half of the industry: MRT outperforms 64.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.32
MRT Yearly Current Assets VS Current LiabilitesMRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

MRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.39%.
The Revenue has decreased by -6.84% in the past year.
EPS 1Y (TTM)-87.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.39%
Revenue 1Y (TTM)-6.84%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-48.82%

3.2 Future

MRT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.04% yearly.
The Revenue is expected to grow by 68.50% on average over the next years. This is a very strong growth
EPS Next Y27.66%
EPS Next 2Y35.01%
EPS Next 3Y28.04%
EPS Next 5YN/A
Revenue Next Year104.64%
Revenue Next 2Y109.92%
Revenue Next 3Y97.75%
Revenue Next 5Y68.5%

3.3 Evolution

MRT Yearly Revenue VS EstimatesMRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRT Yearly EPS VS EstimatesMRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRT. In the last year negative earnings were reported.
Also next year MRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRT Price Earnings VS Forward Price EarningsMRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRT Per share dataMRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

MRT's earnings are expected to grow with 28.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.01%
EPS Next 3Y28.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARTI TECHNOLOGIES INC

NYSEARCA:MRT (10/3/2025, 8:04:02 PM)

2.41

+0.07 (+2.99%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)09-22 2025-09-22/bmo
Earnings (Next)N/A N/A
Inst Owners13.36%
Inst Owner Change7.19%
Ins Owners33.74%
Ins Owner Change0%
Market Cap189.69M
Analysts77.78
Price Target5.25 (117.84%)
Short Float %0.07%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.44%
PT rev (3m)9.64%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.17
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.24
BVpS-0.42
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -183.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.96%
Cap/Sales 5.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.32
Altman-Z -5.4
F-Score5
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.39%
EPS Next Y27.66%
EPS Next 2Y35.01%
EPS Next 3Y28.04%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.84%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-48.82%
Revenue Next Year104.64%
Revenue Next 2Y109.92%
Revenue Next 3Y97.75%
Revenue Next 5Y68.5%
EBIT growth 1Y-118.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year93.92%
EBIT Next 3Y37.37%
EBIT Next 5Y27.85%
FCF growth 1Y-32.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.69%
OCF growth 3YN/A
OCF growth 5YN/A